A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin.

Trial Profile

A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Enzastaurin (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms PRELUDE
  • Sponsors Eli Lilly
  • Most Recent Events

    • 23 May 2016 Results published in the Journal of Clinical Oncology.
    • 10 Dec 2013 Results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
    • 12 Jun 2013 Planned End Date changed from 1 Aug 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top